Hims & Hers Health (HIMS) Long-Term Debt Issuances (2019 - 2021)
Hims & Hers Health (HIMS) reported Long-Term Debt Issuances of $1.2 million for Q1 2021, up 1832.92% sequentially from $61720.0 in Q4 2019.
Hims & Hers Health (HIMS) Long-Term Debt Issuances (2019 - 2021) Analysis & Trends
Hims & Hers Health (HIMS) has 2 years of Long-Term Debt Issuances data on file, last reported at $1.2 million in Q1 2021.
- For the quarter ending Q1 2021, Long-Term Debt Issuances changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2021 stood at $1.2 million (changed N/A YoY), and the FY2025 full-year result was $970.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances grew to $1.2 million in Q1 2021, from $61720.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $1.2 million in Q1 2021 to a low of $61720.0 in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.19 Mn |
| Mar 31, 2021 | 1.19 Mn |
| Dec 31, 2019 | 61,720.00 |
| Dec 31, 2019 | 61,720.00 |